India Glycols Limited has announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company’s Board of Directors approved the standalone and consolidated financial statements during a meeting held on November 13, 2026. The results detail revenue, expenses, and profits for both periods, alongside a limited review report from statutory auditors.
India Glycols Announces Q2 and H1 FY27 Financial Results
India Glycols Limited (IGL) has officially disclosed its unaudited financial results for the quarter and half-year ending September 30, 2026. The company’s Board of Directors reviewed and approved these results in a meeting held on November 13, 2026. The announcement details both standalone and consolidated financial performance, covering key metrics such as revenue, expenses, and profit before and after tax.
Key Financial Highlights (Standalone)
For the half-year ended September 30, 2026, India Glycols reported a profit before tax of ₹31.79 crore on a standalone basis. Total income from operations for the same period stood at ₹713.52 crore. The unaudited standalone financial results for the quarter ended September 30, 2026, showed a profit before tax of ₹15.25 crore and total income of ₹358.51 crore.
Consolidated Financial Performance
On a consolidated basis, the profit before tax for the half-year ended September 30, 2026, was ₹64.48 crore, with total income from operations reaching ₹4,919.09 crore. For the second quarter ended September 30, 2026, consolidated profit before tax was ₹15.06 crore, and total income was ₹362.75 crore. These figures reflect the combined performance of the company and its subsidiaries.
Auditor’s Review and Scheme of Arrangement
The financial results have undergone a limited review by the company’s statutory auditors, K.N. Gutgutia & Co. The auditors provided a report dated November 13, 2026. Notably, the results also reflect adjustments related to the Scheme of Arrangement approved by the National Company Law Tribunal, concerning the demerger of the Spirits and Biofuel Undertaking and Biopharma Undertaking. These adjustments impact comparative figures, as detailed in the notes to the financial statements.
Segmental Information
The company has identified ‘Bio-based Specialties and Performance Chemicals’ as its single reportable segment. Segment revenue for the half-year ended September 30, 2026, amounted to ₹712.82 crore (standalone) and ₹4,915.52 crore (consolidated). Segment results before interest and tax also reflect this single-segment reporting structure.
Source: BSE
